Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.

IF 3.9 3区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Pharmaceutical Biology Pub Date : 2024-12-01 Epub Date: 2024-05-13 DOI:10.1080/13880209.2024.2351940

Kefeng Liu, Qiong Li, Xiaojing Lu, Xintong Fan, Yongjie Yang, Wei Xie, Jian Kang, Shusen Sun, Jie Zhao

{"title":"Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.","authors":"Kefeng Liu, Qiong Li, Xiaojing Lu, Xintong Fan, Yongjie Yang, Wei Xie, Jian Kang, Shusen Sun, Jie Zhao","doi":"10.1080/13880209.2024.2351940","DOIUrl":null,"url":null,"abstract":"Context: Traditional Chinese medicines (TCMs) have emerged as potential adjuvant therapies to treat non-small cell lung cancer. More direct comparative studies must be conducted among various oral TCMs.Objective: This network meta-analysis evaluates the efficacy and safety of seven oral TCMs combined with chemotherapy in treating NSCLC.Methods: The analysis included Zilongjin, Banmao, Hongdoushan, Huachansu, Kanglaite, Xihuang, and Pingxiao TCMs. Randomized-controlled trials (RCTs) were identified from the following databases: China National Infrastructure, Wanfang, PubMed, Embase, and the Cochrane Library up to April 2023. Two researchers independently extracted data.Results: Sixty-eight RCTs (5,099 patients) were included. Compared to chemotherapy, Banmao capsules [odds ratio (OR) = 2.69, 95% confidence interval (CI) 1.96-3.69)] and Huachansu tablets [OR = 2.35, 95%CI (1.81, 3.05)] ranked in the top two in terms of increasing disease control rate. The two main TCMs to improve the objective response rate were Banmao capsules [OR = 3.49, 95%CI (2.17, 5.60)] and Zilongjin tablets [OR = 2.62, 95%CI (1.92, 3.57)]. Zilongjin tablets [OR = 3.47, 95%CI (2.14, 5.63)] and Huachansu tablets [OR = 3.30, 95%CI (1.65, 6.60)] were ranked as the top two in improving Karnofsky performance status. Hongdoushan capsules (SUCRA = 18.8%) and Banmao capsules (SUCRA = 19.8%) were the top two in reducing gastrointestinal toxicity. Zilongjin tablets (SUCRA = 18.9%) and Banmao capsules (SUCRA = 26.6%) were the top two to reduce liver and kidney toxicity. Hongdoushan capsules (SUCRA = 15.7%) and Huachansu tablets (SUCRA = 16.8%) ranked the top two in reducing thrombocytopenia. Banmao capsules (SUCRA = 14.3%) and Zilongjin tablets (SUCRA = 26.3%) were the top two decreasing leukopenia.Conclusions: Combining oral TCMs with platinum-based chemotherapy has shown superior efficacy compared to platinum-based chemotherapy alone in treating NSCLC.","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095295/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13880209.2024.2351940","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Traditional Chinese medicines (TCMs) have emerged as potential adjuvant therapies to treat non-small cell lung cancer. More direct comparative studies must be conducted among various oral TCMs.

Objective: This network meta-analysis evaluates the efficacy and safety of seven oral TCMs combined with chemotherapy in treating NSCLC.

Methods: The analysis included Zilongjin, Banmao, Hongdoushan, Huachansu, Kanglaite, Xihuang, and Pingxiao TCMs. Randomized-controlled trials (RCTs) were identified from the following databases: China National Infrastructure, Wanfang, PubMed, Embase, and the Cochrane Library up to April 2023. Two researchers independently extracted data.

Results: Sixty-eight RCTs (5,099 patients) were included. Compared to chemotherapy, Banmao capsules [odds ratio (OR) = 2.69, 95% confidence interval (CI) 1.96-3.69)] and Huachansu tablets [OR = 2.35, 95%CI (1.81, 3.05)] ranked in the top two in terms of increasing disease control rate. The two main TCMs to improve the objective response rate were Banmao capsules [OR = 3.49, 95%CI (2.17, 5.60)] and Zilongjin tablets [OR = 2.62, 95%CI (1.92, 3.57)]. Zilongjin tablets [OR = 3.47, 95%CI (2.14, 5.63)] and Huachansu tablets [OR = 3.30, 95%CI (1.65, 6.60)] were ranked as the top two in improving Karnofsky performance status. Hongdoushan capsules (SUCRA = 18.8%) and Banmao capsules (SUCRA = 19.8%) were the top two in reducing gastrointestinal toxicity. Zilongjin tablets (SUCRA = 18.9%) and Banmao capsules (SUCRA = 26.6%) were the top two to reduce liver and kidney toxicity. Hongdoushan capsules (SUCRA = 15.7%) and Huachansu tablets (SUCRA = 16.8%) ranked the top two in reducing thrombocytopenia. Banmao capsules (SUCRA = 14.3%) and Zilongjin tablets (SUCRA = 26.3%) were the top two decreasing leukopenia.

Conclusions: Combining oral TCMs with platinum-based chemotherapy has shown superior efficacy compared to platinum-based chemotherapy alone in treating NSCLC.

查看原文本刊更多论文

七种口服中药联合化疗治疗非小细胞肺癌：一项网络荟萃分析。

背景：中药已成为治疗非小细胞肺癌的潜在辅助疗法。必须对各种口服中药进行更直接的比较研究：本网络荟萃分析评估了七种口服中药联合化疗治疗非小细胞肺癌的有效性和安全性：方法：分析对象包括紫龙胆、板蓝根、红豆杉、华蟾素、康莱特、西黄和平泻药。随机对照试验（RCT）从以下数据库中找到：中国国家数据库、万方数据库、PubMed、Embase 和 Cochrane 图书馆（截至 2023 年 4 月）。两名研究人员独立提取数据：结果：共纳入 68 项 RCT（5099 名患者）。与化疗相比，板蓝根胶囊[几率比（OR）=2.69，95%置信区间（CI）1.96-3.69]和华蟾素片[OR=2.35，95%CI（1.81，3.05）]在提高疾病控制率方面排名前两位。板蓝根胶囊[OR=3.49，95%CI（2.17，5.60）]和紫龙金片[OR=2.62，95%CI（1.92，3.57）]是提高客观反应率的两种主要中药。紫龙金片[OR = 3.47，95%CI (2.14，5.63)]和华蟾素片[OR = 3.30，95%CI (1.65，6.60)]在改善卡诺夫斯基表现状态方面排名前两位。红豆杉胶囊（SUCRA = 18.8%）和板蓝根胶囊（SUCRA = 19.8%）在减少胃肠道毒性方面排名前两位。紫龙金片（SUCRA = 18.9%）和板茂胶囊（SUCRA = 26.6%）在降低肝肾毒性方面位居前两位。红豆杉胶囊（SUCRA = 15.7%）和华蟾素片（SUCRA = 16.8%）在减少血小板减少方面位居前两位。板蓝根胶囊（SUCRA = 14.3%）和紫龙胆片（SUCRA = 26.3%）在减少白细胞减少方面位居前两位：结论：口服中药与铂类化疗联合治疗非小细胞肺癌的疗效优于单用铂类化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Biology 医学-药学

CiteScore

6.70

自引率

2.60%

发文量

191

审稿时长

1 months

期刊介绍： Pharmaceutical Biology will publish manuscripts describing the discovery, methods for discovery, description, analysis characterization, and production/isolation (including sources and surveys) of biologically-active chemicals or other substances, drugs, pharmaceutical products, or preparations utilized in systems of traditional medicine. Topics may generally encompass any facet of natural product research related to pharmaceutical biology. Papers dealing with agents or topics related to natural product drugs are also appropriate (e.g., semi-synthetic derivatives). Manuscripts will be published as reviews, perspectives, regular research articles, and short communications. The primary criteria for acceptance and publication are scientific rigor and potential to advance the field.